5 terminated. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 5 |
| Phase 1 | 1 | Terminated 1 |
Follow Pemphigus: new trials by email Literature Review of Pemphigus trials Research Report on Pemphigus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders Moderna mRNA-1273, BNT162b2, Ad26.COV2.S - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 258 | 2021-08-13 | 2026-06-10 |
| A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) ALXN1830 - Pemphigus, Pemphigus Vulgaris | Phase 1 / Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 8 | 2017-07-18 | 2020-02-05 |
| Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris VAY736, Placebo - Pemphigus Vulgaris | Phase 2 | Terminated | Novartis Pharmaceuticals | 13 | 2013-12-18 | 2021-10-08 |
| Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus intravenous immunoglobulin, cyclophosphamide - Pemphigus Vulgaris | Phase 2 | Terminated | NYU Langone Health | 9 | 2007-04-01 | 2016-02-18 |
| Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris Dapsone - Pemphigus Vulgaris | Phase 2 | Terminated | Jacobus Pharmaceutical | 48 | 1996-11-01 | 2007-02-05 |
Arthritis, Juvenile (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · COVID-19 (1) · Dermatomyositis (1) · Lupus Erythematosus, Systemic (1) · Multiple Sclerosis (1) · Scleroderma, Systemic (1)
Immune System Diseases (5) · Skin Diseases (5) · Skin Diseases, Vesiculobullous (5) · Skin and Connective Tissue Diseases (5) · Autoimmune Diseases (4) · Arthritis (1) · Autoimmune Diseases of the Nervous System (1) · Connective Tissue Diseases (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Infections (1) · Joint Diseases (1) · Lung Diseases (1)
2019-nCoV Vaccine mRNA-1273 (1) · Ad26COVS1 (1) · BNT162 Vaccine (1) · BNT162b5 (1) · COVID-19 Vaccines (1) · Cyclophosphamide (1) · Dapsone (1) · Immunoglobulins, Intravenous (1) · Methotrexate (1) · Mycophenolic Acid (1) · ianalumab (1) · orilanolimab (1)
Alexion Pharmaceuticals, Inc. (1) · Jacobus Pharmaceutical (1) · NYU Langone Health (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novartis Pharmaceuticals (1)
United States (5) · Austria (1) · Bulgaria (1) · Taiwan (1)
Amit Bar-Or, MD, FRCP (1) · Amit Pandya, MD (1) · Diana Chen, MD (1) · Dinesh Khanna, MBBS, MSc (1) · Jean-Claude Bystryn, M.D. (1) · Judith A. James, MD, PhD (1) · M J Rico, MD (1) · Meggan C. Mackay, MD, MS (1) · Michael D Tharp, MD (1) · Natasha Mckerran Ruth, MD (1) · Neil Korman, MD (1) · Stacy Ardoin, MD (1) · Tracey Wright, MD (1) · Victoria P. Werth, MD (1)